A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2021; you can also visit the original URL.
The file type is application/pdf
.
Continuous-infusion von Willebrand factor concentrate is effective for the management of acquired von Willebrand disease
2021
Blood Advances
Acquired von Willebrand disease (aVWD) is a rare disorder associated with a reduction in von Willebrand factor (VWF) activity, leading to increased bleeding risk. Monoclonal gammopathy of undetermined significance (MGUS) is the most common cause of lymphoproliferative disorder-associated aVWD and is caused by accelerated clearance of circulating VWF. Standard VWF replacement protocols for congenital VWD based on intermittent bolus dosing are typically less effective for aVWD because of
doi:10.1182/bloodadvances.2021004843
pmid:34269797
fatcat:lh2xan73mfgrnf3idxsi5lz5my